These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 26630079)

  • 1. Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis.
    Dhayalan A; King BA
    JAMA Dermatol; 2016 Apr; 152(4):492-3. PubMed ID: 26630079
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman.
    Mrowietz U; Gerdes S; Gläser R; Schröder O
    Acta Derm Venereol; 2017 Feb; 97(2):283-284. PubMed ID: 27349217
    [No Abstract]   [Full Text] [Related]  

  • 3. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
    Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
    J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excellent response to tofacitinib treatment in a patient with alopecia universalis.
    Erduran F; Adışen E; Aksakal AB
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):47-49. PubMed ID: 28632888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib as Treatment for Nail Lichen Planus Associated With Alopecia Universalis.
    Iorizzo M; Haneke E
    JAMA Dermatol; 2021 Mar; 157(3):352-353. PubMed ID: 33404596
    [No Abstract]   [Full Text] [Related]  

  • 6. Recovery of nail dystrophy potential new therapeutic indication of tofacitinib.
    Jaller JA; Jaller JJ; Jaller AM; Jaller-Char JJ; Ferreira SB; Ferreira R; Scheinberg M
    Clin Rheumatol; 2017 Apr; 36(4):971-973. PubMed ID: 28210825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alopecia universalis. Partial response to tofacitinib.
    Ruiz-Villaverde R; Cuenca-Barrales C; Linares-Gonzalez L; Ródenas-Herranz T
    Med Clin (Barc); 2019 Aug; 153(3):e15. PubMed ID: 30718001
    [No Abstract]   [Full Text] [Related]  

  • 8. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
    Merola JF; Elewski B; Tatulych S; Lan S; Tallman A; Kaur M
    J Am Acad Dermatol; 2017 Jul; 77(1):79-87.e1. PubMed ID: 28396102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of Alopecia Universalis by Tofacitinib: A Case Report.
    Scheinberg M; Ferreira SB
    Ann Intern Med; 2016 Nov; 165(10):750-751. PubMed ID: 27842401
    [No Abstract]   [Full Text] [Related]  

  • 11. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
    Bayart CB; DeNiro KL; Brichta L; Craiglow BG; Sidbury R
    J Am Acad Dermatol; 2017 Jul; 77(1):167-170. PubMed ID: 28619556
    [No Abstract]   [Full Text] [Related]  

  • 12. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
    Liu LY; Craiglow BG; Dai F; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case Report Highlighting the Effective Treatment of Alopecia Universalis With Tofacitinib in an Adolescent and Adult Patient.
    Patel NU; Oussedik E; Grammenos A; Pichardo-Geisinger R
    J Cutan Med Surg; 2018; 22(4):439-442. PubMed ID: 29463114
    [No Abstract]   [Full Text] [Related]  

  • 14. Tofacitinib for the Treatment of Trachyonychia.
    Zhong X; Liu T; Wei L; Bai J; Fang H; Qiao J
    Am J Ther; 2024 Jul-Aug 01; 31(4):e468-e470. PubMed ID: 38976532
    [No Abstract]   [Full Text] [Related]  

  • 15. Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
    Salman A; Sarac G; Ergun T
    Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata.
    Gordon SC; Abudu M; Zancanaro P; Ko JM; Rosmarin D
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e156-e157. PubMed ID: 30520145
    [No Abstract]   [Full Text] [Related]  

  • 17. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.
    Craiglow BG; King BA
    J Invest Dermatol; 2014 Dec; 134(12):2988-2990. PubMed ID: 24940651
    [No Abstract]   [Full Text] [Related]  

  • 18. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
    Liu LY; Craiglow BG; King BA
    J Am Acad Dermatol; 2018 Feb; 78(2):403-404.e1. PubMed ID: 29108908
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.
    Sandborn WJ; Ghosh S; Panes J; Vranic I; Wang W; Niezychowski W;
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1485-93.e2. PubMed ID: 24480677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
    Craiglow BG; Liu LY; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.